Aspergillosis Clinical Trial
Official title:
A Prospective, Non-Intervention, Observational Assessment of the Correlation Between Circulating Biomarkers of Fungal Bioburden and Clinical Outcome in the Setting of Invasive Aspergillosis
The purpose of this study is to evaluate the relationship between fungal biomarker levels during anti-fungal therapy and the success of treatment for fungal infection. The primary hypothesis is that over the initial two weeks of anti-fungal therapy, fungal biomarkers from participants with invasive aspergillosis (IA) will be lower for those with a successful clinical outcome compared to those with a failed clinical outcome.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT01887457 -
Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy
|
Phase 2 | |
| Completed |
NCT00940017 -
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
|
Phase 4 | |
| Enrolling by invitation |
NCT01617759 -
Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous System Aspergillosis
|
||
| Terminated |
NCT03905447 -
The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
|
Phase 2 | |
| Recruiting |
NCT04744454 -
Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
|
||
| Completed |
NCT02715570 -
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
|
Phase 1 | |
| Withdrawn |
NCT01622595 -
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
|
N/A | |
| Completed |
NCT00001937 -
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
|
Phase 3 | |
| Completed |
NCT04935463 -
Mucormycosis in COVID-19
|
||
| Withdrawn |
NCT01188759 -
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT00473252 -
Surveillance of Fungal Infections During Construction Activity
|
N/A | |
| Completed |
NCT00037206 -
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04818853 -
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
|
||
| Completed |
NCT00412893 -
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
|
Phase 3 | |
| Recruiting |
NCT06135597 -
Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection
|
||
| Terminated |
NCT02646800 -
Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp
|
Phase 4 | |
| Completed |
NCT00388167 -
Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection
|
Phase 4 | |
| Completed |
NCT05065658 -
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
|
||
| Completed |
NCT00005912 -
Voriconazole to Prevent Systemic Fungal Infections in Children
|
Phase 1 | |
| Completed |
NCT04431804 -
THYME AND CARVACROLL Nanoparticle Effect on Fungi
|